N2-(Benzo[d]oxazol-6-yl)-N4-cyclopropyl-5-(trifluoromethyl)pyrimidine-2,4-diamine

ID: ALA4800057

Chembl Id: CHEMBL4800057

PubChem CID: 118905711

Max Phase: Preclinical

Molecular Formula: C15H12F3N5O

Molecular Weight: 335.29

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  FC(F)(F)c1cnc(Nc2ccc3ncoc3c2)nc1NC1CC1

Standard InChI:  InChI=1S/C15H12F3N5O/c16-15(17,18)10-6-19-14(23-13(10)21-8-1-2-8)22-9-3-4-11-12(5-9)24-7-20-11/h3-8H,1-2H2,(H2,19,21,22,23)

Standard InChI Key:  ZMGUVTBINPLWRA-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4800057

    ---

Associated Targets(Human)

ULK1 Tchem Serine/threonine-protein kinase ULK1 (1002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ULK2 Tchem Serine/threonine-protein kinase ULK2 (652 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 335.29Molecular Weight (Monoisotopic): 335.0994AlogP: 3.95#Rotatable Bonds: 4
Polar Surface Area: 75.87Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: 12.33CX Basic pKa: 3.99CX LogP: 2.93CX LogD: 2.93
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.75Np Likeness Score: -1.34

References

1. Ren H,Bakas NA,Vamos M,Chaikuad A,Limpert AS,Wimer CD,Brun SN,Lambert LJ,Tautz L,Celeridad M,Sheffler DJ,Knapp S,Shaw RJ,Cosford NDP.  (2020)  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.,  63  (23): [PMID:33200929] [10.1021/acs.jmedchem.0c00873]

Source